119 related articles for article (PubMed ID: 23463087)
1. Hyaluronic acid as a marker of sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy for colorectal liver metastases: don't forget the tumor.
Rahbari NN; Weitz J
Ann Surg Oncol; 2013 May; 20(5):1405-7. PubMed ID: 23463087
[No Abstract] [Full Text] [Related]
2. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
6. Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases.
Robinson SM; White SA
Histopathology; 2012 Dec; 61(6):1247-8. PubMed ID: 23043422
[No Abstract] [Full Text] [Related]
7. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
9. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Khan AZ; Morris-Stiff G; Makuuchi M
J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
[TBL] [Abstract][Full Text] [Related]
10. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
[TBL] [Abstract][Full Text] [Related]
12. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases.
Rubbia-Brandt L; Mentha G; Terris B
J Am Coll Surg; 2006 Jan; 202(1):199-200. PubMed ID: 16377516
[No Abstract] [Full Text] [Related]
13. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.
Cayet S; Pasco J; Dujardin F; Besson M; Orain I; De Muret A; Miquelestorena-Standley E; Thiery J; Genet T; Le Bayon AG
Eur J Radiol; 2017 Sep; 94():180-190. PubMed ID: 28712693
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-Induced Sinusoidal Obstruction Syndrome Masquerading as Colorectal Liver Metastasis: A Case Report.
Gupta V; Chopde A; Patkar S; Deodhar K; Goel M
J Gastrointest Cancer; 2023 Jun; 54(2):682-686. PubMed ID: 35666356
[TBL] [Abstract][Full Text] [Related]
16. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
17. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy.
Seo AN; Kim H
Clin Mol Hepatol; 2014 Mar; 20(1):81-4. PubMed ID: 24757663
[No Abstract] [Full Text] [Related]
18. [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review].
Baumgaertner I; Ratziu V; Vaillant JC; Hannoun L; Poynard T; André T
Bull Cancer; 2010 May; 97(5):559-69. PubMed ID: 20167564
[TBL] [Abstract][Full Text] [Related]
19. Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: "a note of caution".
Pelegrina A; Martí J; Miquel R; Ferrer J; Hernández-Gea V; Diaz A; Nadal C; García-Valdecasas JC; Fuster J
World J Surg Oncol; 2017 Dec; 15(1):224. PubMed ID: 29246174
[TBL] [Abstract][Full Text] [Related]
20. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation.
Fried MW; Duncan A; Soroka S; Connaghan DG; Farrand A; Peter J; Strauss RM; Boyer TD; McDonald GB
Bone Marrow Transplant; 2001 Mar; 27(6):635-9. PubMed ID: 11319594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
